clinical trial – Page 213 – Communicable Diseases Research

Obesity: A critical risk factor in the COVID ‐19 pandemic

Review

Published on 2020-08-282022-10-31
Journal: Clinical obesity [Category] COVID-19, MERS, SARS,

Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial

코로나19 환자의 탯줄유래 중간엽줄기세포치료제: 임상 1상

Article

Published on 2020-08-272022-08-13
Journal: Signal Transduction and Targeted Therapy [Category] Fulltext, MERS, 임상, 치료법,

[키워드] aberrant immune response Adverse adverse event adverse events analyzed anti-SARS-CoV-2 antibody assigned both groups Cell Chest computed tomography clinical evaluation Clinical symptoms clinical trial Computed tomography control group coronavirus disease Coronavirus disease 2019 COVID-19 Cytokines death discharged double-blinded Drug development drug treatments enrolled evaluate events facial flushing Fever group Hospitalization hospitalized patient Host-directed therapies Human hypoxia IgG and IgM IgM anti-SARS-CoV-2 antibodies immune responses IMPROVE infusion intravenous intravenous infusion Laboratory parameters Long-term follow-up long-term functional disability long-term treatment Mechanical mechanical ventilation Mesenchymal stem cells MSCs No effective drug non-randomized one patient outcome PaO Patient patients with moderate performed phase Phase 1 pulmonary disease Randomized receiving reduce regimens required Safe serious COVID-19 severe COVID-19 stem cell Stem cell therapy Stem-cell research survivor therapeutic use therapy tissue damage Treatment treatment group Trial Two patient two patients UC-MSC UC-MSCs umbilical Ventilation with COVID-19
[DOI] 10.1038/s41392-020-00286-5 PMC 바로가기 [Article Type] Article

Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: study protocol for a randomized, controlled trial

Study Protocol

Published on 2020-08-272022-10-29
Journal: Trials [Category] COVID-19, MERS,

Quality Assessment of the Chinese Clinical Trial Protocols Regarding Treatments for Coronavirus Disease 2019

Pharmacology

Published on 2020-08-272022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

[키워드] 2019 novel coronavirus allocation concealment assessment autonomous baseline China Chinese clinical clinical trial clinically conducted coronavirus disease Coronavirus disease 2019 COVID-19 cross-sectional analysis description effective Effectiveness Efficacy and safety eligibility criteria evaluate exclusion criteria finding high risk indicated Intervention investigator knowledge majority Medicine Methodological quality methodology ongoing trial Open-label outcome measures patients with COVID-19 Potential treatment protocol protocols Quality random Randomized controlled trial Randomized Controlled Trial protocol RCT recruitment regions registry remained Result risk robust screened selection bia sequence Spread Standard study inclusion subject Therapies therapy translation Treatment treatments for COVID-19 Trial trial protocol
[DOI] 10.3389/fphar.2020.01330 PMC 바로가기 [Article Type] Pharmacology

The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19

Review

Published on 2020-08-262022-10-30
Journal: Journal of Translational Medicine [Category] COVID-19, MERS,

[키워드] 1,25(OH)₂D₃ 1918 influenza 25(OH)D acute infectious disease acute respiratory distress Acute respiratory infection acute respiratory syndrome case fatality rates caused children clinical symptom clinical trial concern coronavirus coronavirus disease Coronavirus-2 COVID-19 CRS Cytokine release syndrome death disease Diseases dry cough Emergency expression Extra-renal Factor Factors Fever flu-like symptoms function headache helping homeostasis IL-6 immunologically immunomodulation imperative incidence individual induction Infection inhibiting interleukin-6 key pro-inflammatory pathway Local Loss of Smell metabolism molecular mechanism Necrosis nerve Neurotrophin NF-kB NGF Novel coronavirus nuclear Pain pandemic physician Pneumonia Prevent previous study Prophylactic Public recent reduce reducing Regulation reported Respiratory failure respiratory tract SARS-CoV-2 Sepsis severe symptom severity Shortness of breath skeletal SLE suggested suppression the SARS-CoV-2 TNF treat Treatment treatment for COVID-19 Viral pneumonia Vitamin Vitamin D Vitamin D Metabolism Vitamin D supplementation vitamin D’ while World Health Organization
[DOI] 10.1186/s12967-020-02488-5 PMC 바로가기 [Article Type] Review

High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial

COVID-19에 따른 급성 호흡곤란 증후군에 대한 고용량 덱사메타손 치료: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-08-262022-08-13
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 active cancer acute respiratory distress acute respiratory distress syndrome Adult patients advance directives Advanced cancer age alpha error anticipated approved ARDS assessment assigned bilateral pulmonary infiltrates Blinding block breast-feeding Buenos Aires capture cardiac disease CEMIC clinical clinical trial code Complete concealed Confirmed COVID-19 COVID-19, Dexamethasone, Acute Respiratory Distress Syndrome, Randomised controlled trial, protocol, Steroids delirium develop Dexamethasone diagnosis of SARS-CoV-2 directive discharge disease dissemination do not resuscitate dose Effectiveness element End-Expiratory Pressure evaluate exclusion criteria Expiratory Pressure explained failure followed by Frequency glucocorticoid Glucocorticoids group hemodynamic High dose HIV infection hypoxemic Hypoxemic respiratory failure ICU Immunosuppression Immunosuppressive agents include inclusion criteria Infection Informed consent intensive care unit International legal guardian Length less Life expectancy local Ethics Committee mechanical ventilation Mortality multicenter muscle weakness Nosocomial infection Nosocomial infections number objective open open label open trial other disease other diseases outcome Palliative care PaO parallel group participant Participation Patient Patient care platform Pneumonia Positive end-expiratory pressure power power of 80% Prednisone pressure Prone position protocol R language random randomised randomised controlled trial randomization Randomized randomized clinical trial receive recruitment Registered renal renal disease respiratory respiratory distress Respiratory distress syndrome Respiratory failure resuscitate order RT-PCR Sample size SARS-COV-2 infection SARS-CoV-2 pneumonia secondary Secondary outcomes secondary to sequence Sequential Organ Failure Assessment severe immunosuppression SOFA Standard deviation status Stratified randomization Study protocol subject Support syndrome table terminal Terminal disease title Treatment treatment groups Trial Trial registration two-tailed alpha error Variation ventilator ventilator-free day Ventilator-free days ventilatory Version viral shedding weakness website women
[DOI] 10.1186/s13063-020-04646-y PMC 바로가기 [Article Type] Letter

Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2

현재 임상 시험 프로토콜 및 SARS-CoV-2에 대한 면역화를 위한 글로벌 노력

Review

Published on 2020-08-252022-09-10
Journal: Vaccines [Category] 비임상,

[키워드] absence acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 affecting Asia Brazil breath Candidates ChAdOx1 Characteristics clinical clinical trial clinical trials collaboration coronavirus coronavirus disease Coronavirus disease 2019 country COVID-19 current dissemination effective effort Health immunization inactivated Intervention Local MOST mRNA-based vaccine mRNA1273 outbreak platform Prevention strategy purified research and development (R&D) respiratory SARS-CoV-2 SARS-CoV-2 vaccine Scientific community selected severe acute respiratory syndrome Coronavirus systematic review treatment for COVID-19 United Arab Emirates United Kingdom USA Vaccine Vaccine development Viral Viral vector
[DOI] 10.3390/vaccines8030474 PMC 바로가기 [Article Type] Review

Impact of Shenfu injection on a composite of organ dysfunction development in critically ill patients with coronavirus disease 2019 (COVID-19): A structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-08-242022-10-29
Journal: Trials [Category] COVID-19, MERS,

[키워드] 1:1 28-day mortality 48 hours adopted allergic allergy allocation concealment alveolar baseline bleeding blinded Blinding block randomization both group breastfeeding women caused China Chinese clinical clinical trial conducted control group coronavirus disease COVID-19 criteria Critical Critically ill patient death defined determine Diagnosis dissemination distribution element enrolled enrolment event exacerbated expected HIV hospital hospital cost ICU immunosuppressive drug Impact incidence include increase in injection intensive care Length lung malignant tumor management guideline multicenter National Health Commission number objective Obstructive Open-label organ organ dysfunction Organ failure outcome parallel group participant Patient patient recruitment patients patients with COVID-19 Pneumonia pregnant primary endpoint protocol provided pulmonary interstitial fibrosis random randomised randomised controlled trial randomization Randomized Randomized controlled trial Randomly receive recruit recruited researchers Sample size SAS sealed secondary endpoint Sepsis Seven severe malnutrition severity Shenfu injection shown SOFA SOFA score statistical status study group Study protocol supportive therapy the patient Total treat Treatment Two-arm underlying disease usual care vasoactive drug Volume website
[DOI] 10.1186/s13063-020-04677-5 PMC 바로가기 [Article Type] Letter

Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials

Letter

Published on 2020-08-242022-10-29
Journal: Trials [Category] Coronavirus, MERS,

[키워드] administration Analysis ARMS asked assessment Characteristics Chinese clinical trial Comparator group comparison Corticosteroid COVID-19 Critically ill patient defined Dexamethasone disease severity dissemination dose Effect element eligible EudraCT Evidence greater group heterogeneity High dose Hydrocortisone information Interaction Intervention intervention effect intervention group investigator ISRCTN less low dose meta-analyses Meta-analysis meta-regression Methylprednisolone Mortality Network meta-analysis objective Odds ratio Open-label outcome p-values participant Patient per day Placebo placebo-controlled primary analysis Prospective protocol provided quantified random-effect randomised controlled trial randomization Randomized Randomized controlled trials randomized trial Research Risk of bias RoB 2 secondary Serious Adverse Events Standard of care steroid Study protocol subgroup subgroups systematic review the WHO therapeutic dose therapy Treatment Trial trials usual care website WHO
[DOI] 10.1186/s13063-020-04641-3 PMC 바로가기 [Article Type] Letter

Immune Dysfunction and Multiple Treatment Modalities for the SARS-CoV-2 Pandemic: Races of Uncontrolled Running Sweat?

Review

Published on 2020-08-242022-10-28
Journal: Biology [Category] COVID-19,

[키워드] acute respiratory syndrome adoptive cell-based therapy anti-neoplastic regimen Antigen caused cells chimeric clinical trial clinical trials Community confirmed case coronavirus coronavirus disease COVID-19 Cytokine storm death deregulation Extracellular Extracellular vesicles global pandemic high mortality Host immune Immune cell immunomodulatory immunomodulatory drugs Infection lack Mesenchymal stem cells modality Multiple natural killer outcome pharmaceutical intervention Protective race receptors reduce regenerative regimen regimens risk running SARS-CoV-2 SARS-CoV-2 pathogenesis selected shown Spread Stem cell therapy the SARS-CoV-2 therapeutic therapeutic strategy therapy Treatment treatment strategy uncontrolled Vaccine
[DOI] 10.3390/biology9090243 PMC 바로가기 [Article Type] Review